Acalabrutinib (Calquence) is a prescription medicine used to treat adult patients with mantle cell lymphoma (MCL). It works by blocking a protein called Bruton's tyrosine kinase (BTK). BTK is a type of enzyme that helps control the growth and spread of certain cells, such as B-cells. By blocking BTK, Acalabrutinib may help reduce the growth and spread of cancer cells.
Acalabrutinib, sold under the brand name Calquence, is a medication classified as a selective inhibitor of Bruton tyrosine kinase (BTK). It is primarily used to treat various types of blood cancers and is considered a targeted therapy. Here's a breakdown of its key aspects:
Type of drug:
- Targeted therapy: Acalabrutinib works by specifically targeting a protein called Bruton tyrosine kinase (BTK), which plays a crucial role in the survival and growth of certain cancer cells. By inhibiting BTK, Acalabrutinib disrupts these processes and helps to slow or stop the progression of cancer.
Conditions treated:
- Mantle cell lymphoma (MCL): Acalabrutinib is approved for the treatment of adults with MCL who have received at least one prior treatment. MCL is a rare type of B-cell non-Hodgkin lymphoma (NHL) that affects the immune system.
- Chronic lymphocytic leukemia (CLL): Acalabrutinib is also indicated for the treatment of adults with CLL who have received at least one prior therapy. CLL is a slow-growing cancer of the white blood cells.
- Marginal zone lymphoma (MZL): Acalabrutinib is used to treat adults with MZL who have received at least one prior treatment. MZL is a rare type of NHL that affects the lymphoid tissue in the spleen and lymph nodes.
Mechanism of action:
- As mentioned earlier, Acalabrutinib targets BTK, a protein crucial for the survival and growth of various B-cell malignancies. By inhibiting BTK, Acalabrutinib disrupts several processes essential for cancer cell growth and survival, including:
- Cell proliferation (division)
- Migration (movement)
- Survival
Administration:
- Acalabrutinib is administered orally as capsules, typically taken twice daily with or without food.
Important to remember:
- Acalabrutinib is a prescription medication and should only be used under the supervision of a qualified healthcare professional.
- It is not a cure for cancer, but it can help to slow or stop the progression of the disease and improve survival outcomes in patients with specific types of blood cancers.
- Acalabrutinib can cause side effects, including fatigue, headache, diarrhea, cough, and muscle pain. It's crucial to discuss the potential risks and benefits with your doctor before starting treatment.
Disclaimer: This information is for general knowledge purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis, treatment, and personalized recommendations for any medical condition.